bioRxivCancer BiologyPreprint
Improved Tumor Blood Flow Enhances the Abscopal Effect: Preclinical Assessment in Mice Treated with Combined Radiation and PD-1 Blockade Therapy
Kota YamashitaiD, Jeffrey BrenderiD, Yu Saida, Yasunori OtowaiD, Horie Kazumasa, Takeshi ItoiD, Kazutoshi YamamotoiD, Helmut Merkle, William Marston LinehaniD, Murali Cherukuri KrishnaiD, Shun KishimotoiD
- Citations
- 2
Abstract
The abscopal effect, where localized radiation therapy induces regression of distant metastatic lesions through immune activation, shows promise for treating metastatic cancer but occurs inconsistently. Here we demonstrate that tumor perfusion critically influences systemic immune responses to combination therapy with radiation and PD-1 blockade. Using multimodal imaging including DCE-MRI, EPR oximetry, and hyperpolarized 13C-MRI, we show that successful abscopal responses in MC38 tumors are characterized by enhanced perfusion, reduced hypoxia, decreased cellularity, and lower glycolytic activity in remote tumors. Notably, pre-treatment perfusion metrics (AUC1min) and extracellular volume (AUC10min) in primary tumors predict subsequent growth of remote tumors, while the same measurements in remote tumors lack predictive value. Based on these findings, we enhanced the abscopal effect by exposing mice to carbogen (95% O2 + 5% CO2) during radiation therapy. Carbogen exposure increased tumor perfusion by 71% (AUC1min) and significantly improved systemic responses in the checkpoint blockade responsive MC38 model but not in the poorly responsive B16.F10 tumors. The enhanced response correlated with increased activation of CD8+ T cells in tumor-draining lymph nodes and elevated serum HMGB-1 levels. RNA sequencing revealed significant extracellular matrix remodeling in carbogen-treated tumors. These results establish tumor perfusion as both a predictive biomarker and a modifiable determinant of systemic immune responses, suggesting that perfusion-based patient stratification and vascular modification strategies could improve outcomes in combination immunotherapy and radiation treatment.
- organism: mouse
- assay: imaging
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Early Radiation Therapy Response Assessment using Multi-scale Photoacoustic Imaging
Thierry L Lefebvre, Mariam‐Eleni Oraiopoulou, … Sarah E. Bohndiek·Advanced SciencePeer-reviewed·Mar 9, 2026
- Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer
Lincoln N. Strickland, MacKenzie V. Demmel, … Jennifer M. Bailey·bioRxiv·Jul 1, 2026
- Immune-metabolic PET/MRI uncovers microenvironmental reprogramming under combined immunotherapy and anti-angiogenic therapy
Sixing Li, Marie-Aline C. Neveu, … André F. Martins·bioRxiv·Aug 7, 2026
- Detecting Early Response to Immune Checkpoint Blockade by Multimodal Molecular Imaging
Y. Saida, J. R. Brender, … S. Kishimoto·Cancer ResearchPeer-reviewed·Jul 1, 2021
- Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation
Seung Young Lee, Joanna Pagacz, … Stephen J. Kron·CancersPeer-reviewed·Jan 24, 2025
- Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity
P. Kroon, E. Frijlink, … I. Verbrugge·bioRxiv·Jun 29, 2018